Esprit™ BTK System, The first-and-only FDA-approved drug-eluting resorbable scaffold for CLTI

Esprit™ BTK Everolimus Resorbable Scaffold System is an innovative new treatment for chronic limb-threatening ischemia (CLTI) patients that is designed to expand the luminal diameter of infrapopliteal lesions without the limitations of a permanent metallic implant.
Learn more: bit.ly/45b3Ooh
Important Safety Info: bit.ly/4dD39it
Connect with us on social media:
X - / abbottcardio
LinkedIn - / abbott-cardiovascular